search
Back to results

PCT-guided Treatment Regarding Antibiotic Use for Acute COPD Exacerbations (PRECISION)

Primary Purpose

COPD Exacerbation, COPD, Acute Copd Exacerbation

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Procalcitonin
Physician's decision
Sponsored by
Erasmus Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for COPD Exacerbation focused on measuring Procalcitonin

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: COPD, according to GOLD 2018 definition Indication for hospitalization because of acute severe exacerbation of COPD, as defined by GOLD 2018 and modified Anthonisen criteria Presence of at least 2 major symptoms of the modified Anthonisen criteria (acute deterioration in sputum volume, sputum purulence and dyspnea) or the presence of 1 major symptom and 1 minor symptom (coughing, wheeze, nasal discharge, sore throat, fever) Post-bronchodilator FEV1/FVC < 0,70 and FEV1% < 80%pred. within last 5 years At least 40 years Smokers or ex-smokers with > 10 packyears Written informed consent Start of symptoms no more than 7 days before admission Exclusion Criteria: Indication for ICU and or non-invasive ventilation < 72h of admission Pneumonia, radiologically confirmed Infection at another site and/or sepsis according to the SIRS criteria (with tachycardia and tachypnea not being caused by the exacerbation) COPD before age 40 Asthma, without presence of COPD. Patients with COPD , with or without a history of asthma (in childhood or as an adolescent) will NOT be excluded/are allowed to participate. Patients with Asthma/COPD overlap syndrome (with current asthma AND COPD) will NOT be excluded/are allowed to participate. Clinically relevant heart failure or myocardial ischemia Chronic use of immunosuppressants, including prednisolone (a prednisone equivalent of 10mg or less is allowed/is NOT an exclusion criterion) Known bronchiectasis as a primary diagnosis Colonisation with Pseudomonas spp. or other micro-organisms in recent cultures (last 60 days) not susceptible to amoxicillin-clavulanic acid Pregnancy Recent exacerbation (last 28 days)

Sites / Locations

  • Zuyderland hospital
  • Amphia hospitalRecruiting
  • Catharina hospital
  • Bravis hospital
  • Noordwest hospital groupRecruiting
  • OLVGRecruiting
  • MST Enschede
  • Isala kliniekenRecruiting
  • Groene HartRecruiting
  • Erasmus MC
  • Franciscus Gasthuis & VlietlandRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

PCT-guided treatment

Usual care

Arm Description

Patients randomized to this arm will only receive antibiotic treatment when the procalcitonin concentration is > 0.25ug/L.

Patients randomized to this arm will receive antibiotic treatment based on the physician's decision.

Outcomes

Primary Outcome Measures

Treatment failure
Treatment failure is defined as disease-related mortality, need for endotracheal intubation or vasopressors, renal failure (defined as Kidney Disease: Improving Global Outcomes (KDIGO) stage 3 - new renal replacement therapy, tripling of baseline creatinine, or serum creatinine > or = 350 umol/L), lung abcess/empyema, development of pneumonia or rehospitalization within 30 days after inclusion.

Secondary Outcome Measures

Incomplete resolution of the clinical signs and symptoms
Incomplete resolution of the clinical signs and symptoms associated with the AECOPD at day 30 after inclusion of the study (i.e. not reaching the baseline condition prior to the AECOPD) scored using the modified Anthonisen criteria
Incomplete resolution of the clinical signs and symptoms
Incomplete resolution of the clinical signs and symptoms associated with the AECOPD at day 30 after inclusion of the study (i.e. not reaching the baseline condition prior to the AECOPD) scored using the modified Anthonisen criteria
Modified Anthonisen criteria
Patients fill in the modified Anthonisen criteria card on day 1 as a baseline measure
Modified Anthonisen criteria
Patients fill in the modified Anthonisen criteria card on day 3
Modified Anthonisen criteria
Patients fill in the modified Anthonisen criteria card on day 1 as a baseline measure
Modified Anthonisen criteria
Patients fill in the modified Anthonisen criteria card on day 1 as a baseline measure
Decision to start antibiotic therapy after an initial opposite decision (after 48 hours)
Decision to start antibiotic therapy after an initial opposite decision (after 48 hours)
Side effects of antibiotic treatment
Side effects of antibiotic treatment, such as gastro-intestinal complaints, allergic reactions
Cumulative antibiotic consumption
The cumulative amount of antibiotic treatment consumed by the patient during follow-up
Cumulative prednisolone consumption
The cumulative amount of prednisolone consumed by the patient during follow-up
Length of hospitalization
Duration of time (in days) of the admission in hospital for the index exacerbation during follow-up
Re-exacerbation
The presence of a new exacerbation, requiring treatment (prednisolone and/or antibiotic treatment) during follow-up
EXACT respiratory questionnaire
PROM symptom score: EXACT - Respiratory symptoms scale
EXACT respiratory questionnaire
PROM symptom score: EXACT - Respiratory symptoms scale
EXACT respiratory questionnaire
PROM symptom score: EXACT - Respiratory symptoms scale
EXACT respiratory questionnaire
PROM symptom score: EXACT - Respiratory symptoms scale
CAT
COPD assessment test, quality of life questionnaire
CAT
COPD assessment test, quality of life questionnaire
CAT
COPD assessment test, quality of life questionnaire
CAT
COPD assessment test, quality of life questionnaire
EQ-5D-5L
quality of life questionnaire
EQ-5D-5L
quality of life questionnaire
EQ-5D-5L
quality of life questionnaire
EQ-5D-5L
quality of life questionnaire
iMCQ
Medical consumption questionnaire, measuring the total amount of medical consumption (admission, ER visits, outpatient visits) during follow-up
Non-invasive ventilation after 72 hours of admission
Need for non-invasive ventilation after 72 hours of admission
Time to complete resoluation of symptoms
· Time to complete resolution of symptoms according to daily symptom diaries evaluating the modified Anthonisen criteria

Full Information

First Posted
February 14, 2023
Last Updated
May 9, 2023
Sponsor
Erasmus Medical Center
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
search

1. Study Identification

Unique Protocol Identification Number
NCT05854901
Brief Title
PCT-guided Treatment Regarding Antibiotic Use for Acute COPD Exacerbations
Acronym
PRECISION
Official Title
Procalcitonin-guided Treatment Regarding Antibiotic Use for Acute COPD Exacerbations: a Prospective Randomised Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 10, 2021 (Actual)
Primary Completion Date
February 2025 (Anticipated)
Study Completion Date
February 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Erasmus Medical Center
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study the investigators will examine whether procalcitonin-guided treatment regarding antibiotic therapy is non-inferior to usual care in patients who are admitted because of an acute COPD exacerbation when it comes to treatment failure on day 30.
Detailed Description
Chronic obstructive pulmonary disease (COPD) is a prevalent disease, worldwide, and in the Netherlands with approximately 600.000 patients. COPD is currently the 3rd leading cause of death worldwide and is also a leading cause of disability-adjusted life years. Given the contribution of exacerbations both to loss in quality of life and to health-care costs, it is of paramount importance to improve the current treatment of exacerbations. Pulmonary physicians are well aware of overuse of antibiotics, but lack the tools to decide which medication to give in the clinical setting. Biomarkers may aid towards a more personalized treatment of acute COPD exacerbations (AECOPD). Procalcitonin (PCT), the precursor of calcitonin, is released in response to a bacterial infection by many tissues within 6-12 hours after the onset of infection, while the concentration is only minimally raised in viral infections, making it a relative specific diagnostic tool for bacterial infection. Several trials have shown a reduction in antibiotic consumption in AECOPD when using a PCT-guided treatment algorithm. Recent systematic reviews concluded that appropriately powered trials are lacking to confirm that clinical outcomes are comparable with usual care. In this study the investigators will examine whether a PCT-guided treatment regarding antibiotic therapy is non-inferior to usual care in patients who are admitted because of an acute COPD exacerbation when it comes to treatment failure on day 30.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COPD Exacerbation, COPD, Acute Copd Exacerbation
Keywords
Procalcitonin

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This is a prospective randomized clinical multi-center study to evaluate procalcitonin-guided treatment regarding antibiotic use in patients who are admitted because of an acute COPD exacerbation. Patients who are admitted are randomly assigned to either procalcitonin-guided treatment (in which antibiotics are started when the procalcitonin concentration is above 0.25 ng/mL) or usual care in which the treating physician decides whether or not to start with antibiotic treatment. Patients will be stratified for study center.
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
693 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PCT-guided treatment
Arm Type
Experimental
Arm Description
Patients randomized to this arm will only receive antibiotic treatment when the procalcitonin concentration is > 0.25ug/L.
Arm Title
Usual care
Arm Type
Active Comparator
Arm Description
Patients randomized to this arm will receive antibiotic treatment based on the physician's decision.
Intervention Type
Diagnostic Test
Intervention Name(s)
Procalcitonin
Other Intervention Name(s)
PCT
Intervention Description
blood test, measuring the concentration of PCT in ug/L
Intervention Type
Other
Intervention Name(s)
Physician's decision
Intervention Description
The physician's decided whether the patient will receive antibiotic treatment or not
Primary Outcome Measure Information:
Title
Treatment failure
Description
Treatment failure is defined as disease-related mortality, need for endotracheal intubation or vasopressors, renal failure (defined as Kidney Disease: Improving Global Outcomes (KDIGO) stage 3 - new renal replacement therapy, tripling of baseline creatinine, or serum creatinine > or = 350 umol/L), lung abcess/empyema, development of pneumonia or rehospitalization within 30 days after inclusion.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Incomplete resolution of the clinical signs and symptoms
Description
Incomplete resolution of the clinical signs and symptoms associated with the AECOPD at day 30 after inclusion of the study (i.e. not reaching the baseline condition prior to the AECOPD) scored using the modified Anthonisen criteria
Time Frame
change between baseline and after 30 days
Title
Incomplete resolution of the clinical signs and symptoms
Description
Incomplete resolution of the clinical signs and symptoms associated with the AECOPD at day 30 after inclusion of the study (i.e. not reaching the baseline condition prior to the AECOPD) scored using the modified Anthonisen criteria
Time Frame
day 30
Title
Modified Anthonisen criteria
Description
Patients fill in the modified Anthonisen criteria card on day 1 as a baseline measure
Time Frame
baseline
Title
Modified Anthonisen criteria
Description
Patients fill in the modified Anthonisen criteria card on day 3
Time Frame
day 3
Title
Modified Anthonisen criteria
Description
Patients fill in the modified Anthonisen criteria card on day 1 as a baseline measure
Time Frame
day 5
Title
Modified Anthonisen criteria
Description
Patients fill in the modified Anthonisen criteria card on day 1 as a baseline measure
Time Frame
day 10
Title
Decision to start antibiotic therapy after an initial opposite decision (after 48 hours)
Description
Decision to start antibiotic therapy after an initial opposite decision (after 48 hours)
Time Frame
30 days
Title
Side effects of antibiotic treatment
Description
Side effects of antibiotic treatment, such as gastro-intestinal complaints, allergic reactions
Time Frame
30 days
Title
Cumulative antibiotic consumption
Description
The cumulative amount of antibiotic treatment consumed by the patient during follow-up
Time Frame
30 days
Title
Cumulative prednisolone consumption
Description
The cumulative amount of prednisolone consumed by the patient during follow-up
Time Frame
30 days
Title
Length of hospitalization
Description
Duration of time (in days) of the admission in hospital for the index exacerbation during follow-up
Time Frame
up to 30 days
Title
Re-exacerbation
Description
The presence of a new exacerbation, requiring treatment (prednisolone and/or antibiotic treatment) during follow-up
Time Frame
30 days
Title
EXACT respiratory questionnaire
Description
PROM symptom score: EXACT - Respiratory symptoms scale
Time Frame
change between baseline and after 30 days
Title
EXACT respiratory questionnaire
Description
PROM symptom score: EXACT - Respiratory symptoms scale
Time Frame
baseline
Title
EXACT respiratory questionnaire
Description
PROM symptom score: EXACT - Respiratory symptoms scale
Time Frame
day 10
Title
EXACT respiratory questionnaire
Description
PROM symptom score: EXACT - Respiratory symptoms scale
Time Frame
day 30
Title
CAT
Description
COPD assessment test, quality of life questionnaire
Time Frame
baseline
Title
CAT
Description
COPD assessment test, quality of life questionnaire
Time Frame
day 10
Title
CAT
Description
COPD assessment test, quality of life questionnaire
Time Frame
day 30
Title
CAT
Description
COPD assessment test, quality of life questionnaire
Time Frame
change between baseline and day 30
Title
EQ-5D-5L
Description
quality of life questionnaire
Time Frame
baseline
Title
EQ-5D-5L
Description
quality of life questionnaire
Time Frame
day 10
Title
EQ-5D-5L
Description
quality of life questionnaire
Time Frame
day 30
Title
EQ-5D-5L
Description
quality of life questionnaire
Time Frame
change between baseline and day 30
Title
iMCQ
Description
Medical consumption questionnaire, measuring the total amount of medical consumption (admission, ER visits, outpatient visits) during follow-up
Time Frame
30 days
Title
Non-invasive ventilation after 72 hours of admission
Description
Need for non-invasive ventilation after 72 hours of admission
Time Frame
30 days
Title
Time to complete resoluation of symptoms
Description
· Time to complete resolution of symptoms according to daily symptom diaries evaluating the modified Anthonisen criteria
Time Frame
30 days
Other Pre-specified Outcome Measures:
Title
Cost-effective analysis
Description
Alongside the clinical trial, an economic evaluation will be performed conform the guidelines of the Health Care Institute Netherlands (17). This evaluation will be conducted from a societal and payer's perspective. When adopting the societal perspective, costs will include 30-day inpatient and outpatient (emergency room, specialist visits) hospital costs, primary care costs (visits to GP and nurse practitioner), medication costs, ambulance costs, productivity costs, informal care costs and travel costs.
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: COPD, according to GOLD 2018 definition Indication for hospitalization because of acute severe exacerbation of COPD, as defined by GOLD 2018 and modified Anthonisen criteria Presence of at least 2 major symptoms of the modified Anthonisen criteria (acute deterioration in sputum volume, sputum purulence and dyspnea) or the presence of 1 major symptom and 1 minor symptom (coughing, wheeze, nasal discharge, sore throat, fever) Post-bronchodilator FEV1/FVC < 0,70 and FEV1% < 80%pred. within last 5 years At least 40 years Smokers or ex-smokers with > 10 packyears Written informed consent Start of symptoms no more than 7 days before admission Exclusion Criteria: Indication for ICU and or non-invasive ventilation < 72h of admission Pneumonia, radiologically confirmed Infection at another site and/or sepsis according to the SIRS criteria (with tachycardia and tachypnea not being caused by the exacerbation) COPD before age 40 Asthma, without presence of COPD. Patients with COPD , with or without a history of asthma (in childhood or as an adolescent) will NOT be excluded/are allowed to participate. Patients with Asthma/COPD overlap syndrome (with current asthma AND COPD) will NOT be excluded/are allowed to participate. Clinically relevant heart failure or myocardial ischemia Chronic use of immunosuppressants, including prednisolone (a prednisone equivalent of 10mg or less is allowed/is NOT an exclusion criterion) Known bronchiectasis as a primary diagnosis Colonisation with Pseudomonas spp. or other micro-organisms in recent cultures (last 60 days) not susceptible to amoxicillin-clavulanic acid Pregnancy Recent exacerbation (last 28 days)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michael L van Schaik, MD/MSc
Phone
+31615283010
Email
m.l.vanschaik@erasmusmc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Menno M van der Eerden, MD, PhD
Email
m.vandereerden@erasmusmc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Menno M van der Eerden, MD, PhD
Organizational Affiliation
Erasmus Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Zuyderland hospital
City
Heerlen
State/Province
Limburg
ZIP/Postal Code
6419PC
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frank LJ Custers, MD
Email
f.custers@zuyderland.nl
Facility Name
Amphia hospital
City
Breda
State/Province
Noord-Brabant
ZIP/Postal Code
4818CK
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Remco Djamin, MD, PhD
Email
rdjamin@amphia.nl
Facility Name
Catharina hospital
City
Eindhoven
State/Province
Noord-Brabant
ZIP/Postal Code
5623 EJ
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frank Smeenk, MD PhD prof
Email
frank.smeenk@catharinaziekenhuis.nl
Facility Name
Bravis hospital
City
Roosendaal
State/Province
Noord-Brabant
ZIP/Postal Code
4708AE
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marieke Kuipers - de Heer, MD, PhD
Email
m.deheer@bravis.nl
Facility Name
Noordwest hospital group
City
Alkmaar
State/Province
Noord-Holland
ZIP/Postal Code
1800AM
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Astrid Aardenburg, MD, PhD
Email
a.aardenburg-van.huisstede@nwz.nl
First Name & Middle Initial & Last Name & Degree
Lisa Hessels, MD
Email
lm.hessels@nwz.nl
Facility Name
OLVG
City
Amsterdam
State/Province
Noord-Holland
ZIP/Postal Code
1091AC
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul Bresser, MD, PhD
Email
p.bresser@olvg.nl
First Name & Middle Initial & Last Name & Degree
Hjalmar de Graaff, MD
Email
h.j.degraaff@olvg.nl
Facility Name
MST Enschede
City
Enschede
State/Province
Overijssel
ZIP/Postal Code
7500KA
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wendy JC van Beurden, MD, PhD
Email
w.vanbeurden@mst.nl
First Name & Middle Initial & Last Name & Degree
Ellen Lohuis - Goossen
Email
w.lohuis-goossen@mst.nl
Facility Name
Isala klinieken
City
Zwolle
State/Province
Overijssel
ZIP/Postal Code
8025 AB
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael L van Schaik
Phone
+31615283010
Email
m.l.vanschaik@erasmusmc.nl
First Name & Middle Initial & Last Name & Degree
Jan WK van der Berg, MD, PhD
Email
j.w.k.van.den.berg@isala.nl
Facility Name
Groene Hart
City
Gouda
State/Province
Zuid-Holland
ZIP/Postal Code
2803HH
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yordi PA van Dooren, MD
Email
yordi.van.dooren@ghz.nl
First Name & Middle Initial & Last Name & Degree
Kim van Elst
Email
kim.van.elst@ghz.nl
Facility Name
Erasmus MC
City
Rotterdam
State/Province
Zuid-Holland
ZIP/Postal Code
3015GD
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Menno M van der Eerden, MD, PhD
Email
m.vandereerden@erasmusmc.nl
First Name & Middle Initial & Last Name & Degree
Michael L van Schaik, MD
Phone
+31615283010
Email
m.l.vanschaik@erasmusmc.nl
Facility Name
Franciscus Gasthuis & Vlietland
City
Rotterdam
State/Province
Zuid-Holland
ZIP/Postal Code
3045PM
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hans in 't Veen, MD, PhD
Email
h.intveen@franciscus.nl
First Name & Middle Initial & Last Name & Degree
Geer Janne Baakman, MD
Email
g.baakman@franciscus.nl

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://trialsearch.who.int/Trial2.aspx?TrialID=NL9122
Description
Netherlands Trial Register registration included in ICTRP

Learn more about this trial

PCT-guided Treatment Regarding Antibiotic Use for Acute COPD Exacerbations

We'll reach out to this number within 24 hrs